CoChat
Sign Up
Cited by 101Electroconvulsive Therapy StudiesTreatment of Major DepressionMemory and Neural Mechanisms

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Induction of Cyclin-Dependent Kinase 5 in the Hippocampus by Chronic Electroconvulsive Seizures: Role of ΔFosB

Open access
Chen, Jingshan, Zhang, Yajun, Kelz, Max B., Steffen, Cathy, Ang, Eugenius S., Zeng, Ling, Nestler, Eric J.·2000·The Journal of Neuroscience
DOI 10.1523/jneurosci.20-24-08965.2000
Open this paper in CoChat — free accountOpen PDF

Abstract

The transcription factor ΔFosB is induced in the hippocampus and other brain regions by repeated electroconvulsive seizures (ECS), an effective antidepressant treatment. The unusually high stability of this protein makes it an attractive candidate to mediate some of the long-lasting changes in the brain caused by ECS treatment. To understand how ΔFosB might alter brain function, we examined the gene expression profiles in the hippocampus of inducible transgenic mice that express ΔFosB in this brain region by the use of cDNA expression arrays that contain 588 genes. Of the 430 genes detected, 20 genes were consistently upregulated, and 14 genes were downregulated, by >50%. One of the upregulated genes is cyclin-dependent kinase 5 (cdk5). On the basis of its purported role in regulating neuronal structure, we studied directly whether cdk5 is a true target for ΔFosB. Upregulation of cdk5 immunoreactivity in the hippocampus was confirmed by Western blotting in the ΔFosB-expressing transgenic mice as well as in rats treated chronically with ECS. Chronic ECS treatment also increased, in the hippocampus, the phosphorylation state of tau, a microtubule-associated protein that is a known substrate for cdk5. A 1.6 kb fragment of the cdk5 promoter was cloned, and activity of the promoter was found to be increased after overexpression of ΔFosB in cell culture. Moreover, mutation of the single consensus activator protein-1 site contained within the cdk5 promoter fragment completely abolished activation of the promoter by ΔFosB. Together, these results suggest that cdk5 is one target by which ΔFosB produces some of its physiological effects in the hippocampus and thereby mediates certain long-term consequences of chronic ECS treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.20-24-08965.2000

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Identification of cdk5 as one of the downstream target genes for D FosB in the hippocampus of inducible bitransgenic mice using cDNA expression arrays. A , Schematic diagram of the tetracycline expression system used for the inducible tissue-specific expression of D FosB (Chen et al., 1998). Gene 1 encodes the tetracycline transactivator ( tTA ) under the control of the neuron-specific enolase ( NSE ) promoter. Gene 2 encodes D FosB under the control of the tetracycline-responsive promoter with seven tetracycline operators ( TetOp ). B , Strategy for searching downstream target genes for D FosB in the hippocampus of inducible D FosB-expressing bitransgenic mice. Total RNA was isolated from five bitransgenic mice, either expressing or not expressing D FosB, and pooled. Poly(A 1 ) RNA was isolated from the pooled total RNA and used as a template for the synthesis of a 32 P-labeled cDNA probe. The cDNA probes were hybridized to the arrays, and the arrays were analyzed by the PhosphorImager. C , Gene expression profiles of the hippocampus of the bitransgenic mice, either expressing or not expressing D FosB, from a portion of the resulting cDNA expression arrays. Positions of the D FosB and cdk5 genes are indicated by arrows . The results are representative of three independent determinations.
Figure 1 Identification of cdk5 as one of the downstream target genes for D FosB in the hippocampus of inducible bitransgenic mice using cDNA expression arrays. A , Schematic diagram of the tetracycline expression system used for the inducible tissue-specific expression of D FosB (Chen et al., 1998). Gene 1 encodes the tetracycline transactivator ( tTA ) under the control of the neuron-specific enolase ( NSE ) promoter. Gene 2 encodes D FosB under the control of the tetracycline-responsive promoter with seven tetracycline operators ( TetOp ). B , Strategy for searching downstream target genes for D FosB in the hippocampus of inducible D FosB-expressing bitransgenic mice. Total RNA was isolated from five bitransgenic mice, either expressing or not expressing D FosB, and pooled. Poly(A 1 ) RNA was isolated from the pooled total RNA and used as a template for the synthesis of a 32 P-labeled cDNA probe. The cDNA probes were hybridized to the arrays, and the arrays were analyzed by the PhosphorImager. C , Gene expression profiles of the hippocampus of the bitransgenic mice, either expressing or not expressing D FosB, from a portion of the resulting cDNA expression arrays. Positions of the D FosB and cdk5 genes are indicated by arrows . The results are representative of three independent determinations.CC-BY-NC-SA · From the PDF
Figure 2 Upregulation of cdk5 immunoreactivity in the hippocampus of inducible bitransgenic mice after D FosB expression. A , A representative immunoblot shows cdk5 levels in the hippocampus of bitransgenic mice expressing ( 1 ) or not expressing ( 2 ) D FosB. B , Levels of cdk5 immunoreactivity are given as arbitrary OD units and are expressed as the mean 6 SEM ( n 5 5 animals in each treatment group). * p , 0.05 by Student's t test.
Figure 2 Upregulation of cdk5 immunoreactivity in the hippocampus of inducible bitransgenic mice after D FosB expression. A , A representative immunoblot shows cdk5 levels in the hippocampus of bitransgenic mice expressing ( 1 ) or not expressing ( 2 ) D FosB. B , Levels of cdk5 immunoreactivity are given as arbitrary OD units and are expressed as the mean 6 SEM ( n 5 5 animals in each treatment group). * p , 0.05 by Student's t test.CC-BY-NC-SA · From the PDF
Image 3
CC-BY-NC-SA · From the PDF
Figure 3 Induction of cdk5 promoter activity by D FosB. A , Schematic structure of a fragment of the 5 9 -promoter of the cdk5 gene is shown. Several putative response elements within the promoter region are indicated. The AP-1 site f ramed by a rectangular box and its adjacent sequences are shown. The AP-1 sequence in a mutated promoter ( underlined sequence) is also shown. B , Luciferase activity was measured in a C6 glioma cell line that supports the inducible expression of D FosB (Chen et al., 1997) transfected with the wild-type (cdk5-luc) or mutated (mutcdk5-luc) cdk5 promoter in pGL3-basic. Data are expressed as the mean percent change in promoter activity in the presence of D FosB compared with that in the absence of D FosB ( 6 SEM; n 5 3). The results are representative of two independent replications. * p , 0.05 by Student's t test.
Figure 3 Induction of cdk5 promoter activity by D FosB. A , Schematic structure of a fragment of the 5 9 -promoter of the cdk5 gene is shown. Several putative response elements within the promoter region are indicated. The AP-1 site f ramed by a rectangular box and its adjacent sequences are shown. The AP-1 sequence in a mutated promoter ( underlined sequence) is also shown. B , Luciferase activity was measured in a C6 glioma cell line that supports the inducible expression of D FosB (Chen et al., 1997) transfected with the wild-type (cdk5-luc) or mutated (mutcdk5-luc) cdk5 promoter in pGL3-basic. Data are expressed as the mean percent change in promoter activity in the presence of D FosB compared with that in the absence of D FosB ( 6 SEM; n 5 3). The results are representative of two independent replications. * p , 0.05 by Student's t test.CC-BY-NC-SA · From the PDF
Image 5
CC-BY-NC-SA · From the PDF
Figure 4 Upregulation of cdk5 AP-1-binding activity in the hippocampus of inducible bitransgenic mice after D FosB expression. A , The sequence of the cdk5 AP-1 oligonucleotide used as the probe is shown. The 32 P-labeled nucleotides are indicated by dots . B , A representative autoradiogram shows the dramatic induction of cdk5 AP-1-binding activity after D FosB expression. The results are representative of three independent replications.
Figure 4 Upregulation of cdk5 AP-1-binding activity in the hippocampus of inducible bitransgenic mice after D FosB expression. A , The sequence of the cdk5 AP-1 oligonucleotide used as the probe is shown. The 32 P-labeled nucleotides are indicated by dots . B , A representative autoradiogram shows the dramatic induction of cdk5 AP-1-binding activity after D FosB expression. The results are representative of three independent replications.CC-BY-NC-SA · From the PDF
Image 7
CC-BY-NC-SA · From the PDF
Figure 5 Upregulation of cdk5 immunoreactivity in rat hippocampus by chronic ECS treatment. A , Top , A representative immunoblot shows cdk5 levels in the hippocampus after sham or ECS treatment. Bottom , Levels of cdk5 immunoreactivity are given as arbitrary OD units and are expressed as the mean 6 SEM ( n 5 8 animals in each treatment group). B , Top , A representative autoradiogram shows cdk5 AP-1-binding activity after sham or ECS treatment. Bottom , Levels of cdk5 AP-1-binding activity are given as arbitrary OD units and are expressed as the mean 6 SEM( n 5 8 animals in each treatment group). * p , 0.05 by Student's t test.
Figure 5 Upregulation of cdk5 immunoreactivity in rat hippocampus by chronic ECS treatment. A , Top , A representative immunoblot shows cdk5 levels in the hippocampus after sham or ECS treatment. Bottom , Levels of cdk5 immunoreactivity are given as arbitrary OD units and are expressed as the mean 6 SEM ( n 5 8 animals in each treatment group). B , Top , A representative autoradiogram shows cdk5 AP-1-binding activity after sham or ECS treatment. Bottom , Levels of cdk5 AP-1-binding activity are given as arbitrary OD units and are expressed as the mean 6 SEM( n 5 8 animals in each treatment group). * p , 0.05 by Student's t test.CC-BY-NC-SA · From the PDF
Figure 6 Upregulation of tau phosphorylation in rat hippocampus by chronic ECS treatment. A , A representative immunoblot showing levels of phospho-tau proteins after sham or ECS treatment. B-F , Levels of phospho-tau, in arbitrary OD units, for each tau isoform 6 SEM ( n 5 3). * p , 0.05 by Student's t test.
Figure 6 Upregulation of tau phosphorylation in rat hippocampus by chronic ECS treatment. A , A representative immunoblot showing levels of phospho-tau proteins after sham or ECS treatment. B-F , Levels of phospho-tau, in arbitrary OD units, for each tau isoform 6 SEM ( n 5 3). * p , 0.05 by Student's t test.CC-BY-NC-SA · From the PDF
Figure 7 Regulation of p35 and p25 immunoreactivity in rat hippocampus by chronic ECS treatment. A , A representative immunoblot shows p35 and p25 levels after sham or chronic ECS treatment. B , Levels of p35 and p25 immunoreactivity are given as arbitrary OD units and are expressed as the mean 6 SEM ( n 5 8 animals in each treatment group). * p , 0.05 by Student's t test.
Figure 7 Regulation of p35 and p25 immunoreactivity in rat hippocampus by chronic ECS treatment. A , A representative immunoblot shows p35 and p25 levels after sham or chronic ECS treatment. B , Levels of p35 and p25 immunoreactivity are given as arbitrary OD units and are expressed as the mean 6 SEM ( n 5 8 animals in each treatment group). * p , 0.05 by Student's t test.CC-BY-NC-SA · From the PDF
Image 11
CC-BY-NC-SA · From the PDF
Image 12
CC-BY-NC-SA · From the PDF
Image 13
CC-BY-NC-SA · From the PDF
Image 14
CC-BY-NC-SA · From the PDF
Image 15
CC-BY-NC-SA · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Chen, J., Zhang, Y., Kelz, M. B., Steffen, C., Ang, E. S., Zeng, L., & Nestler, E. J.
Affiliations
Yale University (US)
ORCID
Venue
The Journal of Neuroscience
Publisher
Society for Neuroscience
Published
2000-12-15
Volume
20
Issue
24
Pages
8965-8971
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
DOI
10.1523/jneurosci.20-24-08965.2000
OpenAlex
W4322703188
Cited by
101
References
38
Citations by year
2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 4 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 3
FWCI
3.29
Type
journal article
Language
en
Open access
Licence
Locations
Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
Funders
  • National Institute of Mental Health
  • National Institute on Drug Abuse
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
Keywords
ΔFosB, cyclin-dependent kinase 5, electroconvulsive seizures, hippocampus, gene expression profiling, AP-1 transcription factor, tau phosphorylation, transgenic mice, antidepressant treatment, long-term synaptic plasticity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review